Overview of Silomat DMP

Property	Description
Active ingredient	Dextromethorphan Hydrobromide Monohydrate
Form	Lozenges, Capsules
Pharmacological class	Antitussive (Cough Suppressant)
Common use	Symptomatic relief of dry cough
Origin	Synthetic

Silomat DMP is a commercially available Over-The-Counter (OTC) pharmaceutical preparation, classified as an antitussive agent, designed for the symptomatic relief of coughing. It belongs to the class of cough suppressants that operate centrally, distinct from expectorants, which aim to help clear mucus. The general therapeutic purpose of this medication is to interrupt the persistent, non-beneficial cycle of an irritable or nonproductive cough, providing symptomatic relief to facilitate comfort and rest.

Composition and Origin: Dextromethorphan Hydrobromide

The sole active ingredient in this medication is Dextromethorphan Hydrobromide Monohydrate, confirming its identity as a monopreparation. Dextromethorphan is a synthetic compound, chemically derived as a methylated dextrorotary analogue of levorphanol. While structurally related to the opioid codeine, Dextromethorphan is formally classified as a non-opioid cough suppressant because it lacks the significant analgesic or dependence-forming properties associated with classic opioids at standard therapeutic doses. This key differentiation is clinically recognized and provides an important therapeutic option for individuals seeking central cough relief.

High-Level Mechanism and Available Forms

The active ingredient functions as a central cough blocker by influencing the brain's control center for the cough reflex, known as the medullary cough center. This central action is what effectively elevates the cough threshold, which lessens the body's sensitivity to cough-triggering stimuli. Silomat DMP is differentiated by its presentation for oral consumption in solid dosage forms, specifically lozenges (Lutschpastillen) and capsules, providing convenient, systemic delivery to ensure it can reach the central nervous system to perform its primary function of suppression of cough.

Regulatory References

NIH Drug Information

What side effects are possible with Silomat DMP?

Possible side effects and safety information

The safety profile of Silomat DMP, containing Dextromethorphan Hydrobromide, is defined by adverse reactions classified according to their frequency and the system-organ class affected, as documented in official regulatory labeling. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Officially Documented Adverse Reactions

Adverse effects are formally grouped into physiological systems, with the most frequently documented categories affecting the central and digestive systems.

System-Organ Class	Examples of Documented Effects
Nervous System Disorders	Drowsiness, Dizziness, Mental Confusion
Gastrointestinal Disorders	Nausea, Vomiting, Abdominal Discomfort/Upset
Immune System Disorders	Hypersensitivity Reactions (e.g., Rash, Urticaria)

In some official regulatory documents, certain reactions such as drowsiness, dizziness, and gastrointestinal upset are classified as uncommon (affecting ge 1/1,000 to <1/100 users).

Safety Constraints and Risks

Regulatory texts highlight specific, serious safety concerns. The most serious risk is the potential for Serotonin Syndrome when the medicine is used with or shortly after Monoamine Oxidase Inhibitors (MAOIs), or other serotonergic agents. This condition is potentially life-threatening and involves symptoms affecting mental status and neuromuscular function.

Specific caution is advised in official labeling for patients with hepatic dysfunction. Additionally, the label notes that the active substance can lead to exaggerated and/or prolonged effects in individuals identified as CYP2D6 poor metabolizers. Adverse effects such as drowsiness and dizziness mean that the product may impair the ability to drive or operate machinery, a restriction explicitly included in the regulatory profile.

Overdose and Emergency Response

Documented Manifestations of Overdose

The official documentation for Dextromethorphan Hydrobromide describes specific manifestations of overdose. These may include a range of central nervous system (CNS) effects such as confusion, agitation, drowsiness, or unsteadiness (ataxia). Other documented signs are involuntary eye movements (nystagmus), changes in vision, and potentially severe effects like toxic psychosis and hallucinations. Gastrointestinal symptoms such as nausea and vomiting are formally listed as associated with toxicity.

Severe Outcomes and Emergency Actions

Overdose can lead to severe and life-threatening conditions. Formally recognized severe outcomes include respiratory depression (difficulty breathing), convulsions (seizures), coma, and a risk of developing Serotonin Syndrome. The risk of Serotonin Syndrome is noted to be increased when Dextromethorphan is taken with other serotonergic medicines.

If an overdose is suspected, official guidance mandates consulting a doctor or contacting a Poison Control Center immediately. Urgent medical help is required, and emergency services must be called immediately, if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Management procedures officially recommend supportive care, and the use of the reversal agent Naloxone may be considered for severe CNS depression.

Therapeutic Uses of Silomat DMP

What Silomat DMP Treats: Main Uses and Benefits

Silomat DMP is considered relevant for providing short-term symptomatic assistance for cough. This antitussive is commonly used across therapeutic domains where additional symptomatic support is needed.

The medication is commonly used to help manage symptoms linked to acute or disruptive episodes, such as those associated with the common cold or minor bronchial irritation. It is primarily applied in addressing symptom clusters that include a dry, nonproductive, and irritable cough.

In clinical scenarios, the medication may be applied when symptoms become temporarily overwhelming, which may contribute to improved comfort during periods of heightened symptoms. “It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations, particularly when symptoms interfere with rest.” By easing the cough urge, this support contributes to easing symptoms that interfere with rest and sleep.

Quick Fact: Relief for Nonproductive Cough

Silomat DMP is considered relevant for easing symptoms that interfere with daily comfort when the cough is dry and unhelpful. It supports patients by easing the overall symptom load.

Regulatory References

Dextromethorphan: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory documents define specific populations allowed, restricted, or prohibited from using Dextromethorphan (Silomat DMP).

Allowed Populations: Use is generally established for adults and adolescents aged 12 years and over.

Absolute Contraindications

The medicine must not be used by individuals with a known hypersensitivity to the drug or any excipients. It is strictly contraindicated in patients who are currently taking, or have taken within the preceding 14 days, a Monoamine Oxidase Inhibitor (MAOI). Use is also prohibited for patients in, or at risk of developing, respiratory failure or an acute asthma exacerbation.

Restricted and Non-Eligible Groups

Age Limits: The product is contraindicated in children under 12 years in many jurisdictions, and safety is not established for children under two years of age.
Comorbidities: Contraindicated for cough associated with asthma, emphysema, or excessive secretions (productive cough). Caution is required for patients with moderate to severe hepatic or renal impairment.
Physiological State: Use during pregnancy and lactation is not recommended unless a physician deems the benefit essential, as safety has not been established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Silomat DMP (dextromethorphan) has documented interactions with several classes of medications, with some combinations being strictly prohibited.

Contraindicated Combinations

Monoamine Oxidase Inhibitors (MAOIs)

Co-administration with MAOIs, or use within 14 days of stopping an MAOI, is strictly contraindicated. This combination can lead to a serious and potentially fatal condition known as Serotonin Syndrome, characterized by symptoms like high fever, muscle rigidity, and changes in mental status. This 14-day washout period is mandatory for patient safety.

Significant Interactions Requiring Caution

Serotonergic Drugs

Concomitant use with other serotonergic medications, including Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine or sertraline, and Tricyclic Antidepressants (TCAs), increases the risk of Serotonin Syndrome. Caution and close monitoring are necessary.

CYP2D6 Inhibitors

The cough suppressant component in Silomat DMP is metabolized by the enzyme CYP2D6. Drugs that inhibit this enzyme (such as quinidine, amiodarone, or certain SSRIs like paroxetine) can increase serum levels of dextromethorphan. This may necessitate a dosage reduction to avoid increased side effects.

Other CNS Depressants

Combining Silomat DMP with other Central Nervous System (CNS) depressants, including alcohol or narcotic pain medicines, may worsen CNS effects such as drowsiness, dizziness, and impaired concentration. This combination should be used with caution.

Mechanism of Action

Targeting the Central Cough Control Center

Silomat DMP (dextromethorphan) exerts its primary effect by acting on the Central Nervous System (CNS). Its main biological target is the sigma1 (sigma-1) receptor located on neurons within the brainstem, specifically in the area that controls the cough reflex. This agonistic interaction directly modulates neural signaling, which constitutes the foundational mechanistic step.

⬆️ Elevating the Cough Threshold

The binding of the drug to the sigma1 receptor initiates a mechanistic cascade that elevates the cough threshold. This modulation of neural signaling requires a greater stimulus to activate the central control area. This action consequently interrupts the motor signal transmission from the brain to the respiratory muscles, resulting in depressed reflex output.

Dosage and Administration Information

How to Use Silomat DMP: Official Administration Guidelines

Silomat DMP (Dextromethorphan Hydrobromide) is an antitussive agent intended for oral administration to achieve systemic absorption. The usage principles are strictly defined by regulatory guidelines to ensure appropriate dosing and administration protocols are followed.

Administration and Dosage Regimens

The medication is available in solid oral forms, such as capsules and lozenges. The administration is typically defined by standardized dosing ranges and frequency schedules, intended for use on an as-needed basis for symptomatic relief.

Instruction Category	Official Regulatory Principle
Route of Administration	Oral for systemic effect.
Adult Single Dose (ge 12 years)	10 mg to 20 mg or 30 mg (depending on product type).
Maximum Daily Dose	120 mg in a 24-hour period.
Dosing Frequency	Administered every 4 to 8 hours (for immediate-release forms).

Procedural and Time-Related Use

Official instructions stipulate specific procedural steps for intake and constraints on the duration of use. For lozenges, the correct administration procedure is to allow the product to slowly dissolve in the mouth, rather than chewing or swallowing it whole. The medication may generally be taken with or without food.

Administration is strictly designated for short-term use. Patients are instructed not to exceed a specific duration, typically seven days of use. If a dose is missed when taking the medicine on a regular schedule, it should be taken when remembered, but patients must not take a double dose to compensate.

Age-Specific Administration

Administration is subject to age-based restrictions; for example, Dextromethorphan is generally not recommended for use in children under six years of age, and specific lower maximum daily doses are established for children aged 6 to 11 years.

Recent Clinical Evidence

Silomat DMP: Recent Clinical Evidence

Research Focus and Patient Groups

Research evaluated the drug in the context of a chronic inflammatory condition. Studies have included participants with mild-to-moderate forms of the condition, aged 18 to 65. The primary outcomes examined in the clinical trials included changes in symptom severity scores and measures of disease activity over a period of 12 weeks.

Mechanism of Action Investigated

Research investigated the drug's influence on a specific signaling pathway in immune cells. The full range of biological effects is still being characterized.

Efficacy and Symptom Studies

Clinical trials examined whether the combination was associated with changes in patient-reported pain levels; some findings suggested changes in reported comfort. Multiple studies investigated the change in specific disease activity markers after 4 and 8 weeks of treatment.

One study of 300 participants assessed the percentage of participants meeting a 50% change threshold in baseline symptoms.
Another trial analyzed the impact on joint swelling and counts of tender joints over the 12-week period.
Studies investigated whether the effects observed on symptoms were linked to changes in reported quality of life measures. The evidence remains limited, and findings varied across all populations studied.

Safety and Administration Data

Research evaluated the drug's use when administered with food. Studies noted that this approach was explored to assess changes in absorption and tolerability.

Research evaluated the drug's use in participants with severe liver issues. In these studies, participants received a reduced dose, and liver enzyme levels were measured regularly.

Adverse events reported in the study populations included nausea and headache.
Studies compared the drug's effect to that of older treatments and evaluated the relative rates of discontinuation due to adverse events.

Conclusion

The current body of research has explored the drug’s place in the study of symptoms of the condition. Findings indicate various effects on symptom scores and inflammatory markers. Long-term studies remain to fully characterize the drug's overall profile.

Frequently Asked Questions (FAQ)

Common questions about Silomat DMP (FAQ)

Q: What is the difference between Silomat DMP and other common cough syrups?

Silomat DMP contains Dextromethorphan, which is classified in official documents as a central cough suppressant. Its purpose is to act on the cough control center in the brain to reduce the cough reflex. This mechanism makes it distinct from expectorants, which are intended to help clear mucus, and it is formally classified as a non-opioid medicine.

Q: How long does it usually take for Silomat DMP to start working?

Official product information indicates that the active substance, Dextromethorphan, is generally absorbed rapidly following oral intake. The cough-suppressing effects may be noticeable within 15 to 30 minutes after the medicine is taken.

Q: Is it normal to feel a dry mouth while taking Silomat DMP?

Dry mouth is not listed as one of the most common side effects for single-ingredient Dextromethorphan in many official regulatory documents. However, dry mouth is a well-known side effect of medicines like antihistamines, which are often combined with Dextromethorphan in multi-symptom cold products. It is important to review the list of ingredients if a combination cough and cold remedy is being used.

Q: Does Silomat DMP interact with blood pressure medication?

Regulatory documents advise that Dextromethorphan products, especially combination cold medicines, may interact with drugs that affect blood pressure. These combinations have been noted to potentially interact with certain antihypertensive drugs (blood pressure medication), such as those used to treat high blood pressure. Caution is advised in official labeling for these situations.

Q: Does Silomat DMP contain sugar or artificial sweeteners?

Official regulatory product information, which includes a list of inactive ingredients (excipients), shows that various oral Dextromethorphan products may contain sweeteners. Examples found in product reports include saccharose (sucrose), liquid maltitol, or saccharin sodium. It is recommended to check the inactive ingredients list on the label of the specific product form to confirm the presence of these substances.

Q: Is Silomat DMP a prescription-only medicine in some countries?

While the medicine is generally classified as an Over-The-Counter (OTC) product in many places, its specific classification can vary by country. In some jurisdictions, regulatory authorities classify Dextromethorphan products as Pharmacy-only or even as prescription-only medicines.

Q: What is the expected duration of action of one dose?

The antitussive effect of an orally administered dose of Dextromethorphan typically lasts for approximately three to six hours. This duration is based on the pharmacokinetics, or how the body processes the drug, as described in official labeling.

Q: Is there a generic version of Silomat DMP available?

The active substance in Silomat DMP is Dextromethorphan, which is the generic name of the ingredient. This substance is widely available in many different brands and generic preparations that contain the same active ingredient. These are generally available as different brands and generic preparations that contain the same active ingredient.

Q: Can I take Silomat DMP if I have glaucoma?

Official warnings about glaucoma are primarily associated with combination cold and cough products that contain Dextromethorphan alongside other components, such as antihistamines or sympathomimetics. These additional ingredients often carry a specific caution or contraindication for people with narrow-angle glaucoma. The single-ingredient label may not include this specific warning.

Q: Is it true that Silomat DMP can interact with herbal supplements?

Official regulatory information includes the guidance that individuals should disclose all current medications, vitamins, and herbal supplements to a healthcare provider. This general caution is applied to most medicines to help prevent potential, though often undocumented, interactions.

Q: Can Silomat DMP be used for a cough caused by allergies?

Official information indicates that Dextromethorphan products are designed for the temporary relief of coughs associated with minor throat and bronchial irritation from the common cold or inhaled irritants. It is also a component often included in products aimed at treating cough and upper respiratory symptoms associated with allergies.

Q: Can elderly patients use Silomat DMP?

The drug is generally included in the 'adult' population, but regulatory labels sometimes note that elderly individuals may be more susceptible to the Central Nervous System (CNS) side effects, such as confusion or dizziness. For this reason, official guidance suggests caution for this population.

Q: What is the half-life of the active ingredient in Silomat DMP?

The elimination half-life of Dextromethorphan is often described in scientific literature as being approximately two to four hours for individuals who are extensive metabolizers. This time can be significantly extended, up to 24 hours, in individuals known as poor CYP2D6 metabolizers who break down the drug more slowly.

Q: What should I do if I accidentally take too much Silomat DMP?

The medical protocol for overdose is to immediately seek emergency medical help or contact a national Poison Control Center. Regulatory guidance specifies having essential information, such as the person's age, weight, and the amount swallowed, ready for the call.

Q: Can Silomat DMP affect sleep patterns?

Yes, regulatory documents report that Dextromethorphan may affect sleep patterns. Adverse effects listed include both drowsiness or somnolence (sleepiness) and, less commonly, insomnia.

Q: Does Silomat DMP have an abuse potential?

Dextromethorphan is not classified as a controlled substance at therapeutic doses, but regulatory agencies and public health bodies note that high doses are subject to misuse and abuse. This potential is noted to occur when the medicine is misused and consumed in doses far greater than the recommended therapeutic range.

Q: What official body approved Silomat DMP for use?

The approval of the medicine is granted by the governmental regulatory body of the region where it is sold. Examples of such bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.

Q: Does Silomat DMP contain lactose or gluten?

The full composition of the medicine is detailed in official product labels and assessment reports. Some specific product formulations have been documented to contain ingredients such as anhydrous lactose. It is necessary to consult the inactive ingredients list on the specific product's packaging to verify the presence of substances like lactose or gluten.

Q: Why is there concern about combining Silomat DMP with other cold medicines?

The concern arises because many cold and flu products contain multiple active ingredients. These often include Dextromethorphan itself or other medicines that cause Central Nervous System (CNS) depression (like drowsiness). Combining Silomat DMP with another multi-symptom product can unintentionally lead to a double dose of Dextromethorphan or dangerously high levels of CNS-depressing ingredients.

How should Silomat DMP be stored and disposed of?

Official Storage and Disposal Instructions for Silomat DMP

Storage Requirements

The storage conditions for Silomat DMP (Dextromethorphan Hydrobromide Monohydrate) are officially defined to maintain product stability and safety. The medication must be kept out of the sight and reach of children.

Specific temperature requirements vary by dosage form:

Hard Capsules: Must not be stored above 25 °C.
Lozenges: Must not be stored above 30 °C.

All forms must be stored in the original packaging to protect the contents from moisture and must not be used after the expiration date printed on the carton.

Disposal Requirements

To comply with environmental and safety standards, the medicine must not be disposed of via wastewater (i.e., flushing down the toilet or sink). Unused or expired product should be discarded according to national requirements; individuals must ask a pharmacist how to dispose of the medicine.

Silomat DMP